Pdcd-1 Activators
The class of Pdcd-1 activators comprises a diverse array of chemicals that intricately modulate Pdcd-1 activity, primarily through the inhibition of its interaction with PD-L1 or PD-L2. Monoclonal antibodies such as Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Tremelimumab directly activate Pdcd-1 by blocking these interactions, leading to the relief of T cell suppression and enhanced antitumor immune responses.
Beyond monoclonal antibodies, various small molecules indirectly activate Pdcd-1 by influencing key signaling pathways. Cobimetinib, a MEK inhibitor, modulates the MAPK pathway, while Entinostat, a class I HDAC inhibitor, impacts Pdcd-1 expression through epigenetic regulation. Tyrosine kinase inhibitors like Dasatinib, Entrectinib, and Sunitinib influence Pdcd-1 through Src family kinases, TRKA signaling, and receptor tyrosine kinases, respectively. JAK/STAT pathway modulation by Ruxolitinib and Tofacitinib also indirectly activates Pdcd-1. These activators collectively highlight the intricate interplay between immune checkpoint regulation and various signaling cascades. The direct and indirect activation of Pdcd-1 underscores its pivotal role in mediating immune responses, particularly in the context of cancer immunotherapy. Targeting Pdcd-1 provides a sophisticated toolkit to enhance the antitumor immune response by disrupting inhibitory signals imposed by the PD-1/PD-L1 and PD-1/PD-L2 axes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib is a MEK inhibitor that indirectly activates Pdcd-1 by modulating the MAPK pathway. MEK inhibition leads to reduced ERK activity, influencing Pdcd-1 expression. The indirect activation of Pdcd-1 by Cobimetinib underscores the intricate cross-talk between MAPK signaling and Pdcd-1-associated immune responses, providing a targeted approach to influence Pdcd-1 expression within the context of MAPK pathway modulation. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275 (Entinostat) is a class I HDAC inhibitor that indirectly activates Pdcd-1 by modulating epigenetic regulation. HDAC inhibition influences Pdcd-1 expression through alterations in chromatin accessibility. The indirect activation of Pdcd-1 by Entinostat highlights the role of epigenetic regulation in shaping immune responses, providing a nuanced approach to modulate Pdcd-1 expression and potentially enhance antitumor immune reactions. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that indirectly activates Pdcd-1 by modulating Src family kinases. Inhibition of Src kinases leads to downstream effects on Pdcd-1 expression. The indirect activation of Pdcd-1 by Dasatinib emphasizes the intricate interplay between tyrosine kinase signaling and immune checkpoint regulation, offering a targeted approach to modulate Pdcd-1 expression within the context of Src kinase inhibition. | ||||||
Entrectinib | 1108743-60-7 | sc-507438 | 5 mg | $180.00 | ||
Entrectinib is a tyrosine kinase inhibitor that indirectly activates Pdcd-1 by influencing TRKA signaling. Modulation of TRKA signaling affects downstream pathways, including Pdcd-1 expression. The indirect activation of Pdcd-1 by Entrectinib highlights the cross-talk between tyrosine kinase signaling and immune checkpoint regulation, offering a targeted approach to influence Pdcd-1 expression within the context of TRKA pathway modulation. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a JAK1/JAK2 inhibitor that indirectly activates Pdcd-1 by modulating JAK/STAT signaling. Inhibition of JAK/STAT signaling influences downstream pathways, including Pdcd-1 expression. The indirect activation of Pdcd-1 by Ruxolitinib emphasizes the intricate interplay between JAK/STAT signaling and immune checkpoint regulation, offering a targeted approach to modulate Pdcd-1 expression within the context of JAK/STAT pathway modulation. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that indirectly activates Pdcd-1 by modulating various signaling pathways. Inhibition of receptor tyrosine kinases influences downstream pathways, including Pdcd-1 expression. The indirect activation of Pdcd-1 by Sunitinib highlights the cross-talk between receptor tyrosine kinase signaling and immune checkpoint regulation. | ||||||